AD/PD™ 2027公布科学议程：聚焦阿尔茨海默病与帕金森病的早期检测及新疗法

120-session hybrid conference in Barcelona will bring together leading researchers and clinicians to explore biomarkers, disease mechanisms and novel therapeutic strategies.

, /PRNewswire/ -- AD/PD™, the International Conference on Alzheimer's and Parkinson's Diseases and Related Disorders, has unveiled its scientific program for AD/PD™ 2027, taking place March 16–20, 2027, in Barcelona, Spain, and online. Featuring 120 symposia with over 750 on-site talks and 1,500 Posters and expecting more than 6,000 participants from over 70 countries, the conference will highlight advances in early detection, disease etiology and mechanisms, and novel therapeutic approaches across neurodegenerative diseases.

The program will explore emerging biomarkers, molecular and cellular mechanisms of neurodegeneration, disease-modifying treatments, amyloid-beta (Aβ) immunotherapies, tau-targeted strategies, and novel small-molecule approaches addressing cognitive dysfunction in Alzheimer's disease, alongside therapeutic developments in Parkinson's disease and related disorders.

"For decades, one of the greatest challenges in Alzheimer's, Parkinson's and related neurodegenerative diseases has been understanding their origins and complex mechanisms early enough to intervene meaningfully," said Professor Abraham Fisher, Co-founder and President of AD/PD™. "What excites me most is the convergence of increasingly sensitive biomarkers, deeper mechanistic insights, and a growing diversity of therapeutic approaches—from disease-modifying immunotherapies to novel small molecules targeting cognitive dysfunction. AD/PD™ 2027 offers a unique opportunity to critically evaluate these advances and explore how they may translate into meaningful benefits for patients."

The scientific program encompasses 12 themes organized around three core pillars:

Biomarkers & Precision Diagnostics: Advances in blood-based Alzheimer's biomarkers, emerging alpha-synuclein detection approaches in Parkinson's disease, fluid biomarkers for Lewy body and TDP-43 pathologies, and AI-enabled tools supporting earlier disease identification.
Disease Etiology & Mechanisms: Research into genetic and environmental contributions, neuroinflammation, APOE4-associated lipid dysregulation, amyloid-beta and tau pathology, alpha-synuclein aggregation, mitochondrial dysfunction and other mechanisms underlying neurodegeneration.
Novel Therapies & Disease Modification: A broad spectrum of therapeutic strategies, including Aβ immunotherapies, tau-targeted antibodies, small-molecule approaches to cognitive dysfunction, potential disease-modifying strategies, GBA1-targeted Parkinson's treatments, therapies addressing neuroinflammation, and emerging approaches for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), alongside combination therapies and symptomatic care.

Leading International Plenary Speakers

The conference will feature plenary presentations from internationally recognized experts, including:

Randall Bateman, MD (Washington University School of Medicine in St. Louis) — "Don Price Memorial Lecture: From Alzheimer's Treatment and Blood Tests to Prevention, Brain Aging, and AI-Powered Discovery"
Henrik Zetterberg, MD, PhD (University of Gothenburg / University College London) — "Fluid Biomarkers for Tau Pathophysiology in Alzheimer's Disease—What Do They Reflect and What Can They Be Used For?"
Brit Mollenhauer, MD (University Medical Center Göttingen / Paracelsus-Elena-Klinik) — "Multimodal Biomarkers for Prevention Trials in PD"
Bradley Hyman, MD, PhD (Harvard Medical School / Massachusetts General Hospital) — "Eric N. Birch Memorial Lecture: Molecular Pathology of Lewy Body Diseases"
Rosa Rademakers, PhD (VIB-Antwerp Center for Molecular Neurology) — "Can Genetics Crack Neurodegeneration? From Discovery to Disease Modification?"
Costantino Iadecola, MD (Weill Cornell Medicine) — "How the Neurovasculature Shapes Neurodegeneration: Toward a New Framework"
Beth Stevens, PhD (Harvard Medical School / Boston Children's Hospital) — "How Do Brain Macrophages Shape Cognitive Resilience and Vulnerability in Aging and Disease?"

The full interactive program is available online. Early-bird registration closes December 9, 2026. Media information is available for accredited journalists.

About AD/PD™

Established in 1985, AD/PD™ is a leading international forum connecting scientific discoveries with clinical advances in Alzheimer's disease, Parkinson's disease and related neurodegenerative disorders. Its 2026 conference welcomed approximately 6,000 participants from over 70 countries.

Website: adpd.kenes.com

SOURCE Kenes Group